TriSalus Life Sciences, Inc. (TLSI) Stock Profile — Insider Trades & Financials

Revenue$13.2M

Net Income-$9.8M

EPS$-1.72

Gross Margin86.7%

Market Cap$253.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Mary Szela

CEO & Executive Director

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Founded: 2010

⚡

Core Efficiency

ROE?

28.80%

ROA?

-27.60%

D/E Ratio?

-2.04

Op. Margin?

-24.77%

📊

Profitability Ratios

Net Margin?

-73.86%

Loading company sections...

TriSalus Life Sciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness